TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases

Nature Medicine

Volumn 9, Issue 10, 2003, Pages 1245-1250

  Feldmann, Marc ^a   Maini, Ravinder N ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BETA INTERFERON; C REACTIVE PROTEIN; COMPLEMENTARY DNA; CYTOKINE; ETANERCEPT; IMMUNOGLOBULIN; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 15 RECEPTOR ANTIBODY; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR ANTIBODY; INTERSTITIAL COLLAGENASE; LYMPHOTOXIN; MESSENGER RNA; METHOTREXATE; MONOCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL CULTURE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; DISEASE ACTIVITY; DRUG COST; DRUG EFFICACY; DRUG INFUSION; DRUG RESPONSE; DRUG SAFETY; GENE OVEREXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOHISTOLOGY; IMMUNOREGULATION; LUPUS ERYTHEMATOSUS; LYMPHOCYTE ACTIVATION; LYMPHOMA; MEDIATOR; MEDICAL EDUCATION; MOLECULAR CLONING; NONHUMAN; NOTE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN TARGETING; RECEPTOR UPREGULATION; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SIDE EFFECT; SKIN MANIFESTATION;

EID: 0142041982     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm939     Document Type: Note

References (32)

1. Klareskog, L., Forsum, U., Scheynius, A., Kabelitz, D. & Wigzell, H. Evidence in support of a self perpetuating HLA-DR dependent delayed type cell reaction in rheumatoid arthritis. Proc Natl. Acad. Sci. USA 72, 3632-3636 (1982).
2. Janossy, G. et al. Rheumatoid arthritis: a disease of T-lymphocyte/macrophage immunoregulation. Lancet 2, 839-842 (1981).
3. Bottazzo, G.F., Pujol-Borrell, R., Hanafusa, T. & Feldmann, M. Role of aberrant HLA-DR expression and antigen presentation in the induction of endocrine autoimmunity. Lancet 2, 1115-1119 (1983).
4. Taniguchi, T. et al. Structure and expression of a cloned cDNA for human interleukin-2. Nature 302, 305-310 (1983).
5. Pennica, D. et al. Human tumor necrosis factor: precursor structure expression and homology to lymphotoxin. Nature 312, 724-729 (1984).
6. Yasukawa, L. et al. Structure and expression of human B cell stimulatory factor-2 (BSF-2/IL-6 gene). EMBO J. 6, 2939-2945 (1987).
7. Feldmann, M., Brennan, F.M. & Maini, R.N. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14, 397-440 (1996).
8. Buchan, G. et al. Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1 alpha. Clin. Exp. Immunol. 73, 449-455 (1988).
9. Brennan, F.M., Chantry, D., Jackson, A., Maini, R. & Feldmann, M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2, 244-247 (1989).
10. Haworth, C. et al. Expression of granulocytemacrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha. Eur. J. Immunol. 21, 2575-2579 (1991).
11. Fong, Y. et al. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1β and interleukin 6 appearance during lethal bacteremia. J. Exp. Med. 170, 1627-1633 (1989).
12. Chu, C.Q., Field, M., Feldmann, M. & Maini, R.N. Localization of tumor necrosis factor α in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum. 34, 1125-1132 (1991).
13. Williams, R.O., Feldmann, M. & Maini, R.N. Antitumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. USA 89, 9784-9788 (1992)
14. Keffer, J. et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 10, 4025-4031 (1991).
15. Tracey, K.J. et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330, 662-664 (1987).
16. Elliott, M.J. et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 36, 1681-1690 (1993).
17. Elliott, M.J. et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 344, 1125-1127 (1994).
18. Elliott, M.J. et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344, 1105-1110 (1994).
19. Maini, R.N. et al. Randomized placebo-controlled trial of multiple intravenous infusions of anti-TNFα monoclonal antibody with or without weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41, 1552-1563 (1998).
20. Williams, R.O., Mason, L.J., Feldmann, M. & Maini, R.N. Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc. Natl. Acad. Sci. USA 91, 2762-2766 (1994).
21. Moreland, L.W. et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 337, 141-147 (1997).
22. Weinblatt, M.E. et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibodiy, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 48, 35-45 (2003).
23. ATTRACT Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N. Engl. J. Med. 343, 1594-1602 (2000).
24. ATTRACT Study Group. Sustained improvement in physical function, structural damage, and signs and symptom through 2 years in rheumatoid arthritis patients treated with infliximab (Remicade) and methotrexate. Arthritis Rheum. (in the press).
25. Charles, P. et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J. Immunol. 163, 1521-1528 (1999).
26. Taylor, P.C. et al. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor α blockade in patients with rheumatoid arthritis. Arthritis Rheum. 43, 38-47 (2000).
27. Paleolog, E.M. et al. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum. 41, 1258-1265 (1998).
28. Day, R. Adverse reactions to TNFα inhibitors in rheumatoid arthritis. Lancet 359, 540-541 (2002).
29. Arend, W.P. & Dayer, J.-M. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum. 38, 151-160 (1995).
30. Nishimoto, N. et al. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J. Rheumatol. 30, 1426-1435 (2003).
31. Feldmann, M. & Maini, R.N. Anti-TNFα therapy or rheumatoid arthritis: What have we learned? Annu. Rev. Immunol. 19, 163-196 (2001).
32. van Dullemen, H.M. et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109, 129-135 (1995).